Adriamycin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer

A. Ardizzoni, L. Canobbio, P. Pronzato, L. Repetto, J. Serrano, F. Benvenuto, C. Simonassi, F. Baracco, B. Faravelli, M. Nosenzo

Research output: Contribution to journalArticlepeer-review

Abstract

Thirty-five small cell lung cancer (SCLC) patients were treated with combination chemotherapy including adriamycin, cyclophosphamide, etoposide (ACE). Out of 32 evaluable patients there were 21.9% complete responses and 53.1% partial responses with an overall median survival of 37 weeks (50 weeks for patients with limited disease and 34 weeks for patients with extended disease). Toxicity was generally well tolerated. In conclusion the ACE regimen results in being active and safe in the treatment of SCLC.

Original languageEnglish
Pages (from-to)416-419
Number of pages4
JournalChemioterapia
Volume5
Issue number6
Publication statusPublished - 1986

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Adriamycin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer'. Together they form a unique fingerprint.

Cite this